FOREST LABS
SpecialtyFOREST LABS is a specialty pharmaceutical company with 14 FDA-approved products.
FOREST LABS at a Glance
- Fast trial execution (34 months median completion)
FOREST LABS's Key Drugs
FOREST LABS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
FOREST LABS's Recent FDA Approvals
New NDA/BLA approvals for FOREST LABS over the last two years — novel drugs only, excluding generics and label supplements.
FOREST LABS's Therapeutic Areas
Disease areas where FOREST LABS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
FOREST LABS Pipeline Snapshot
Active clinical trials for FOREST LABS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 10/22 completed
- • Speed: 34 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1951-06-08
- Latest
- 2015-08-10
- Applications
- 17
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges